Truist Financial Corp Purchases 22,192 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Truist Financial Corp raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 59.8% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 59,303 shares of the biopharmaceutical company's stock after buying an additional 22,192 shares during the quarter. Truist Financial Corp owned approximately 0.05% of Regeneron Pharmaceuticals worth $42,243,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Fairfield Financial Advisors LTD bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $37,000. Private Wealth Management Group LLC raised its stake in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $39,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Oppenheimer cut their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Citigroup cut their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Robert W. Baird cut their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. Finally, Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Up 0.6 %

Shares of REGN traded up $4.31 during trading hours on Friday, reaching $700.33. The company's stock had a trading volume of 727,332 shares, compared to its average volume of 923,518. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a market cap of $76.56 billion, a price-to-earnings ratio of 18.29, a P/E/G ratio of 2.30 and a beta of 0.08. The company has a 50 day moving average of $700.02 and a two-hundred day moving average of $886.33. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm earned $11.86 EPS. The company's revenue was up 10.3% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.